

EISNERAMPER

CANCER RESEARCH INSTITUTE, INC.

FINANCIAL STATEMENTS

JUNE 30, 2021 and 2020



CANCER RESEARCH INSTITUTE, INC.

Contents

	<u>Page</u>
Independent Auditors' Report	1
Financial Statements	
Statements of financial position as of June 30, 2021 and 2020	3
Statements of activities for the years ended June 30, 2021 and 2020	4
Statement of functional expenses for the year ended June 30, 2021 (with summarized financial information for 2020)	5
Statement of functional expenses for the year ended June 30, 2020	6
Statements of cash flows for the years ended June 30, 2021 and 2020	7
Notes to financial statements	8

INDEPENDENT AUDITORS' REPORT

Board of Trustees
Cancer Research Institute, Inc.

Report on the Financial Statements

We have audited the accompanying financial statements of the Cancer Research Institute, Inc. (the "Institute"), which comprise the statements of financial position as of June 30, 2021 and 2020, and the related statements of activities, functional expenses, and cash flows for each of the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

The Institute's management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the Institute's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Institute's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.



"EisnerAmper" is the brand name under which EisnerAmper LLP and Eisner Advisory Group LLC provide professional services.

EisnerAmper LLP and Eisner Advisory Group LLC are independently owned firms that practice in an alternative practice structure in accordance with the AICPA Code of Professional Conduct and applicable law, regulations and professional standards. EisnerAmper LLP is a licensed CPA firm that provides attest services, and Eisner Advisory Group LLC and its subsidiary entities provide tax and business consulting services. Eisner Advisory Group LLC and its subsidiary entities are not licensed CPA firms.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Cancer Research Institute, Inc. as of June 30, 2021 and 2020, and the changes in its net assets and its cash flows for each of the years then ended, in accordance with accounting principles generally accepted in the United States of America.

EisnerAmper LLP

EISNERAMPER LLP
New York, New York
October 15, 2021



CANCER RESEARCH INSTITUTE, INC.

Statements of Financial Position

	June 30,	
	<u>2021</u>	<u>2020</u>
ASSETS		
Cash and cash equivalents	\$ 33,017,941	\$ 29,455,207
Contributions and grants receivable, net	37,197,576	37,424,255
Bequests receivable	12,090	86,655
Other receivables	109,931	233,807
Investments	74,840,482	58,149,198
Property and equipment, net	144,870	162,580
Prepaid expenses and other assets	418,519	398,680
Beneficial interest in perpetual trust	<u>806,477</u>	<u>653,814</u>
	<u>\$ 146,547,886</u>	<u>\$ 126,564,196</u>
LIABILITIES AND NET ASSETS		
Liabilities:		
Accounts payable and accrued expenses	\$ 849,150	\$ 444,287
Paycheck Protection Program loan payable	710,150	710,150
Grants and fellowships payable, net	70,340,459	64,875,092
Deferred rent obligation	110,670	120,803
Other liabilities	<u>81,822</u>	<u>79,263</u>
Total liabilities	<u>72,092,251</u>	<u>66,229,595</u>
Commitments and other uncertainty (see Notes C and M)		
Net assets:		
Without donor restrictions:		
Undesignated and available for general activities	42,980,717	31,513,552
Board-designated as endowment	<u>5,931,228</u>	<u>4,539,701</u>
Total net assets without donor restrictions	<u>48,911,945</u>	<u>36,053,253</u>
With donor restrictions:		
Purpose restrictions	21,858,823	20,749,144
Perpetual in nature	<u>3,684,867</u>	<u>3,532,204</u>
Total net assets with donor restrictions	<u>25,543,690</u>	<u>24,281,348</u>
Total net assets	<u>74,455,635</u>	<u>60,334,601</u>
	<u>\$ 146,547,886</u>	<u>\$ 126,564,196</u>

See notes to financial statements.

CANCER RESEARCH INSTITUTE, INC.

Statements of Activities

	Year Ended June 30,					
	2021			2020		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
Operating support and revenues:						
Public support:						
General and trustee	\$ 9,192,028	\$ -	\$ 9,192,028	\$ 8,198,754	\$ -	\$ 8,198,754
Combined federal campaigns	580,051	-	580,051	423,479	-	423,479
Bequests and memorials	3,727,223	-	3,727,223	5,761,396	-	5,761,396
Special events (net of direct benefit to donors of \$127,550 in 2020)	1,140,888	660	1,141,548	1,565,196	15,008	1,580,204
Designated contributions (including in-kind contributions of services of \$589,448 in 2021 and \$564,130 in 2020)	<u>14,582,885</u>	<u>4,235,700</u>	<u>18,818,585</u>	<u>15,476,342</u>	<u>4,380,664</u>	<u>19,857,006</u>
Total public support	<u>29,223,075</u>	<u>4,236,360</u>	<u>33,459,435</u>	<u>31,425,167</u>	<u>4,395,672</u>	<u>35,820,839</u>
Operating revenues:						
Rental income (net of related expenses of \$133,750 in 2021 and \$132,810 in 2020)	17,981	-	17,981	18,188	-	18,188
Investment income allocation	2,931,434	-	2,931,434	2,901,985	-	2,901,985
Miscellaneous	<u>87,868</u>	<u>-</u>	<u>87,868</u>	<u>232,975</u>	<u>-</u>	<u>232,975</u>
Total operating revenues	<u>3,037,283</u>	<u>-</u>	<u>3,037,283</u>	<u>3,153,148</u>	<u>-</u>	<u>3,153,148</u>
Net assets released from restrictions	<u>4,158,974</u>	<u>(4,158,974)</u>	<u>-</u>	<u>4,331,083</u>	<u>(4,331,083)</u>	<u>-</u>
Total operating support and revenues	<u>36,419,332</u>	<u>77,386</u>	<u>36,496,718</u>	<u>38,909,398</u>	<u>64,589</u>	<u>38,973,987</u>
Operating expenses:						
Program services:						
Science, medical and research information, and communications	3,989,133	-	3,989,133	3,910,236	-	3,910,236
Research	<u>27,478,047</u>	<u>-</u>	<u>27,478,047</u>	<u>24,050,615</u>	<u>-</u>	<u>24,050,615</u>
Total program services	<u>31,467,180</u>	<u>-</u>	<u>31,467,180</u>	<u>27,960,851</u>	<u>-</u>	<u>27,960,851</u>
Supporting services:						
Administration	1,510,413	-	1,510,413	1,546,492	-	1,546,492
Marketing and development	2,945,732	-	2,945,732	2,813,295	-	2,813,295
Allowance for uncollectible accounts	<u>-</u>	<u>-</u>	<u>-</u>	<u>3,349,084</u>	<u>-</u>	<u>3,349,084</u>
Total supporting services	<u>4,456,145</u>	<u>-</u>	<u>4,456,145</u>	<u>7,708,871</u>	<u>-</u>	<u>7,708,871</u>
Total expenses	<u>35,923,325</u>	<u>-</u>	<u>35,923,325</u>	<u>35,669,722</u>	<u>-</u>	<u>35,669,722</u>
Increase in net assets from operating activities	496,007	77,386	573,393	3,239,676	64,589	3,304,265
Non-operating activities:						
Net investment income (loss) in excess of investment allocation	12,362,685	1,032,293	13,394,978	(1,554,709)	(210,773)	(1,765,482)
Change in value of perpetual trust	<u>-</u>	<u>152,663</u>	<u>152,663</u>	<u>-</u>	<u>(2,525)</u>	<u>(2,525)</u>
Change in net assets	<u>12,858,692</u>	<u>1,262,342</u>	<u>14,121,034</u>	<u>1,684,967</u>	<u>(148,709)</u>	<u>1,536,258</u>
Net assets, beginning of year	<u>36,053,253</u>	<u>24,281,348</u>	<u>60,334,601</u>	<u>34,368,286</u>	<u>24,430,057</u>	<u>58,798,343</u>
Net assets, end of year	<u>\$ 48,911,945</u>	<u>\$ 25,543,690</u>	<u>\$ 74,455,635</u>	<u>\$ 36,053,253</u>	<u>\$ 24,281,348</u>	<u>\$ 60,334,601</u>

See notes to financial statements.

CANCER RESEARCH INSTITUTE, INC.

Statement of Functional Expenses

Year Ended June 30, 2021

(with summarized financial information for 2020)

	Program Services			Support Services			Totals	
	Science, Medical and Research Information, and Communications	Research	Total	Administration	Marketing and Development	Total	2021	2020
Fellowship program	\$ -	\$ 4,891,080	\$ 4,891,080	\$ -	\$ -	\$ -	\$ 4,891,080	\$ 5,720,957
Designated grants program	-	905,000	905,000	-	-	-	905,000	1,692,560
Clinical accelerator program	-	10,587,793	10,587,793	-	-	-	10,587,793	6,995,498
Technology Prize Award	-	996,244	996,244	-	-	-	996,244	1,000,000
CLIP grants program	-	2,597,930	2,597,930	-	-	-	2,597,930	2,391,600
STAR Program	-	7,500,000	7,500,000	-	-	-	7,500,000	6,250,000
Salaries, benefits and related taxes	1,994,181	-	1,994,181	1,058,085	1,923,155	2,981,240	4,975,421	4,717,352
Professional fees and commissions	1,395,153	-	1,395,153	129,176	332,029	461,205	1,856,358	1,528,249
Printing, postage and supplies	188,253	-	188,253	88,139	260,610	348,749	537,002	649,814
Rent	191,736	-	191,736	238,527	159,037	397,564	589,300	592,702
Telephone	10,009	-	10,009	10,008	10,008	20,016	30,025	40,055
Advertising	176,806	-	176,806	25	239,738	239,763	416,569	258,489
Depreciation and amortization	17,125	-	17,125	9,420	16,269	25,689	42,814	39,913
Travel, catering, and related costs	-	-	-	9,301	-	9,301	9,301	574,351
Insurance expense	-	-	-	55,832	-	55,832	55,832	60,595
Miscellaneous	15,870	-	15,870	45,650	4,886	50,536	66,406	68,863
Total expenses before allowance for uncollectible accounts	3,989,133	27,478,047	31,467,180	1,644,163	2,945,732	4,589,895	36,057,075	32,580,998
Allowance for uncollectible accounts	-	-	-	-	-	-	-	3,349,084
Total expenses	3,989,133	27,478,047	31,467,180	1,644,163	2,945,732	4,589,895	36,057,075	35,930,082
Less:								
Direct benefit to donors	-	-	-	-	-	-	-	(127,550)
Rent	-	-	-	(133,750)	-	(133,750)	(133,750)	(132,810)
Total expenses per statements of activities	\$ 3,989,133	\$ 27,478,047	\$ 31,467,180	\$ 1,510,413	\$ 2,945,732	\$ 4,456,145	\$ 35,923,325	\$ 35,669,722

See notes to financial statements.

CANCER RESEARCH INSTITUTE, INC.

**Statement of Functional Expenses
Year Ended June 30, 2020**

	Program Services			Support Services			Totals
	Science, Medical and Research Information, and Communications	Research	Total	Administration	Marketing and Development	Total	2020
Fellowship program	\$ -	\$ 5,720,957	\$ 5,720,957	\$ -	\$ -	\$ -	\$ 5,720,957
Designated grants program	-	1,692,560	1,692,560	-	-	-	1,692,560
Clinical accelerator program	-	6,995,498	6,995,498	-	-	-	6,995,498
Technology Prize Award	-	1,000,000	1,000,000	-	-	-	1,000,000
CLIP grants program	-	2,391,600	2,391,600	-	-	-	2,391,600
STAR Program	-	6,250,000	6,250,000	-	-	-	6,250,000
Salaries, benefits and related taxes	1,903,877	-	1,903,877	1,003,912	1,809,563	2,813,475	4,717,352
Professional fees and commissions	1,189,480	-	1,189,480	157,076	181,693	338,769	1,528,249
Printing, postage and supplies	178,940	-	178,940	136,261	334,613	470,874	649,814
Rent	193,560	-	193,560	238,585	160,557	399,142	592,702
Telephone	13,381	-	13,381	13,337	13,337	26,674	40,055
Advertising	53,341	-	53,341	1,289	203,859	205,148	258,489
Depreciation and amortization	16,126	-	16,126	8,781	15,006	23,787	39,913
Travel, catering, and related costs	344,648	-	344,648	19,683	210,020	229,703	574,351
Insurance expense	-	-	-	60,595	-	60,595	60,595
Miscellaneous	16,883	-	16,883	39,783	12,197	51,980	68,863
Total expenses before allowance for uncollectible accounts	3,910,236	24,050,615	27,960,851	1,679,302	2,940,845	4,620,147	32,580,998
Allowance for uncollectible accounts	-	-	-	3,349,084	-	3,349,084	3,349,084
Total expenses	3,910,236	24,050,615	27,960,851	5,028,386	2,940,845	7,969,231	35,930,082
Less:							
Direct benefit to donors	-	-	-	-	(127,550)	(127,550)	(127,550)
Rent	-	-	-	(132,810)	-	(132,810)	(132,810)
Total expenses per statements of activities	<u>\$ 3,910,236</u>	<u>\$ 24,050,615</u>	<u>\$ 27,960,851</u>	<u>\$ 4,895,576</u>	<u>\$ 2,813,295</u>	<u>\$ 7,708,871</u>	<u>\$ 35,669,722</u>

See notes to financial statements.

CANCER RESEARCH INSTITUTE, INC.**Statements of Cash Flows**

	Year Ended June 30,	
	<u>2021</u>	<u>2020</u>
Cash flows from operating activities:		
Change in net assets	\$ 14,121,034	\$ 1,536,258
Adjustments to reconcile change in net assets to net cash provided by operating activities:		
Donated securities	(89,645)	(258,534)
Proceeds from sale of donated securities	89,645	258,534
Depreciation and amortization	42,814	39,913
Allowance for uncollectible accounts	-	3,349,084
Net realized and unrealized gains on investments	(17,096,248)	(979,792)
Change in value of beneficial interest in perpetual trust	(152,663)	2,525
Deferred rent	(10,133)	(10,133)
Changes in:		
Contributions and grants receivable, net	226,679	47,735
Bequests receivable	74,565	244,059
Other receivables	123,876	53,332
Prepaid expenses and other assets	(19,839)	85,577
Accounts payable and accrued expenses	404,863	(120,963)
Grants and fellowships payable	5,465,367	(3,129,641)
Other liabilities	<u>2,559</u>	<u>(29,569)</u>
Net cash provided by operating activities	<u>3,182,874</u>	<u>1,088,385</u>
Cash flows from investing activities:		
Purchases of office equipment	(25,104)	(13,597)
Purchases of long-term investments	(16,052,275)	(15,000,854)
Proceeds from sales of long-term investments	<u>16,457,239</u>	<u>15,241,980</u>
Net cash provided by in investing activities	<u>379,860</u>	<u>227,529</u>
Cash flows from financing activities:		
Proceeds from Paycheck Protection Program loan payable	<u>-</u>	<u>710,150</u>
Net increase in cash and cash equivalents	3,562,734	2,026,064
Cash and cash equivalents, beginning of year	<u>29,455,207</u>	<u>27,429,143</u>
Cash and cash equivalents, end of year	<u>\$ 33,017,941</u>	<u>\$ 29,455,207</u>
Supplemental disclosure of cash flow information:		
Donated services	<u>\$ 589,448</u>	<u>\$ 564,130</u>

See notes to financial statements.

CANCER RESEARCH INSTITUTE, INC.

Notes to Financial Statements June 30, 2021 and 2020

NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES

[1] The Institute:

The Cancer Research Institute, Inc. (the "Institute") was founded in 1953 in New York to foster the field of cancer immunology, in the belief that the body's immune system can be used to control and cure cancer. The Institute supports research with the immediate aim of increasing the understanding of the immune system and with the ultimate goal of developing immunological methods for the prevention and treatment of human cancer. The Institute also functions as a definitive source of public information on cancer immunology and cancer treatment.

The Institute is a not-for-profit corporation exempt from federal income taxes pursuant to Section 501(c)(3) of the U.S. Internal Revenue Code (the "Code") and from state and local taxes under comparable laws.

[2] Basis of accounting:

The financial statements of the Institute have been prepared using the accrual basis of accounting and conform to accounting principles generally accepted in the United States of America ("U.S. GAAP") as applicable to not-for-profit organizations.

[3] Use of estimates:

The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, public support and revenues and expenses, as well as the disclosure of contingent assets and liabilities. Actual results may differ from those estimates.

[4] Operating measure:

Operating revenues and expenses reflect the activities in which the Institute typically engages to fulfill its mission. The Institute utilizes a spending rate in making its annual investment allocation for support of operations. Investment income, including net realized and unrealized gains and losses, earned in excess of or less than the Institute's spending rate, as well as the change in the value of perpetual trust, is recognized as non-operating revenue.

[5] Cash and cash equivalents:

For financial-reporting purposes, the Institute considers all highly liquid instruments purchased with a maturity of three months or less, when purchased, to be cash equivalents, except for those cash equivalent assets held as part of the investment portfolio.

[6] Investments:

The Institute's investments in equity securities, mutual funds, fixed income securities, and exchange traded funds are reported at their fair values in the statements of financial position based on quoted market prices. Cash and cash equivalents held as part of the investment portfolio are also included in the balances reported as investments.

The Institute also has investments in limited partnerships and limited liability companies which are considered to be alternative investments, for which readily determinable fair values do not exist. The fair value of the alternative investments has been estimated based on the respective net asset value ("NAV") per share (or its equivalent unit) of each investment, as reported by the particular investment manager.

CANCER RESEARCH INSTITUTE, INC.

Notes to Financial Statements June 30, 2021 and 2020

NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[6] Investments: (continued)

Investments in limited partnerships and/or limited liability companies where NAV cannot be used as a practical expedient to fair value are valued based on the valuation policies and procedures of the general partners. The general partners perform oversight of the underlying positions, both on an investment level and from a risk perspective. The general partners are also responsible for ensuring that the investments are valued according to the policies and procedures adopted by the partnerships. The Institute places reliance upon those procedures, and it records those investments at fair value as determined by the general partners. Because of the complex management structures and nature of the underlying investments and the inherent uncertainty of the valuation of the alternative investments, the Institute's management and its various investment managers monitor their positions to reduce the risk of potential losses due to changes in fair values or the failure of counterparties to perform on a routine basis. Management believes the carrying amount of the investments in non-publicly traded securities is a reasonable estimate of their fair value. However, such estimated fair values may differ significantly from the values that would have been used had a ready market for these investments existed.

Certain of the Institute's investment managers enter into derivatives contracts held or issued for trading purposes. These investments are subject to various market risks, which arise from changes in securities values and other market conditions. As part of their overall trading strategies, the investment managers may engage in the purchases and sales of index and equity options, for the purpose of generating profit and/or reducing market risk. Due to the level of risk associated with certain investment securities, it is at least reasonably possible that changes in the values of those securities could occur in the near term and that such changes could materially affect the amounts reported in the financial statements.

The Institute's investments, in general, are subject to various risks, such as interest-rate, market, and credit risks. Due to the level of risk associated with certain investment vehicles, it is at least reasonably possible that changes in the values of those securities could occur in the near term and that such changes could materially affect the amounts reported in the financial statements.

Investment transactions are recorded on a trade-date basis. Realized gains and losses on investments sold, and unrealized appreciation and depreciation on investments held, are reported in the statements of activities as increases or decreases in net assets without donor restrictions unless their use is restricted through donor stipulation. Realized gains and losses on investments are determined by comparison of the cost basis to proceeds at the time of disposition. Distributions from limited partnerships and limited liability companies that represent returns of contributed capital reduce the cumulative costs basis of the respective investment. Distributions received from limited partnerships and limited liability companies in excess of the Institute's cumulative cost basis are recognized as realized gains. Unrealized gains and losses on investments are determined by comparing the investment's cost to the fair value at the end of each year. The earnings from dividends and interest are recognized when earned.

Donated securities are recorded at their estimated fair values, or by their net asset values as determined by the Institute's management on the dates of donation. The Institute's policy is to sell the donated securities immediately, and, accordingly, for purposes of the statement of cash flows, donated securities and the proceeds generated from their sale are included within operating activities. With respect to donors' contributions of equity securities, which for example, are: (i) not readily marketable, (ii) the securities of private companies, or (iii) the securities of companies in liquidation, the Institute's policy is to record such items at appraised value at time of donation in the absence of readily determinable fair values, approximating fair value.

Investment expenses include the services of bank trustees, investment managers and custodians. The balances of investment management fees disclosed in Note C are those specific fees charged by the Institute's various investment managers in each fiscal year; however, they do not include those fees that are embedded in various other investment accounts and transactions.

CANCER RESEARCH INSTITUTE, INC.

Notes to Financial Statements June 30, 2021 and 2020

NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[6] Investments: (continued)

In 2010, the Institute entered into a joint venture with the Ludwig Institute for Cancer Research Ltd. and formed a U.S. company named Cancer Vaccine Acceleration Company, LLC ("CVAC"). The members' initial capital contribution was \$200. The purpose of the company is to obtain, hold, and develop intellectual property and other assets related to research and development of a vaccine for cancer, in furtherance of the respective charitable missions of the members.

[7] Office equipment and leasehold improvements:

Office equipment and leasehold improvements are stated at their original costs at the dates of acquisition, or if contributed, at their fair values at the dates of donation, net of accumulated depreciation. The Institute capitalizes items of property and equipment regardless of their cost, that have a useful life greater than one year, whereas minor costs of repairs and maintenance are expensed as incurred. Depreciation is calculated using the straight-line method over the estimated useful lives of three to ten years. Leasehold improvements are recorded at cost and are amortized over the life of the lease.

Management evaluates the recoverability of the investment in long-lived assets on an on-going basis and recognizes any impairment in the year of determination. There were no triggering events during the fiscal years 2021 or 2020 requiring management to test for impairment adjustments to property and equipment. However, it is reasonably possible that relevant conditions could change in the near term and necessitate a change in management's estimate of the recoverability of these assets.

[8] Beneficial interest in perpetual trust:

The Institute has been named as a beneficiary of a perpetual charitable trust which is administered by a third-party trustee. The trust was created independently by a donor and is administered by an outside agent designated by the donor; accordingly, the Institute has neither possession nor control over the assets of the trust.

The Institute reported the asset and recognized contribution revenue with donor restrictions, perpetual in nature, at the fair value of the Institute's interest in the trust assets. Distributions received on the trust assets are reported as revenue without donor restrictions in the statements of activities, in accordance with donor intent. Subsequent changes in fair value of the perpetual trust assets are recorded as a change in the value of perpetual trust in net assets with donor restrictions. At June 30, 2021 and 2020, the fair value of this trust was \$806,477 and \$653,814, respectively.

[9] Deferred rent obligation:

Rent expense is recorded on a straight-line basis over the term of the lease, and includes any concession and rent escalations over the life of the lease agreement. The difference between rental payments made under the terms of the lease agreement and rent expense calculated on a straight-line basis is recorded as a deferred rent obligation in the statements of financial position.

[10] Accrued vacation:

Based on their tenure, the Institute's employees are entitled to be paid for unused vacation time if they leave the Institute's employ. Accordingly, at each fiscal year-end, the Institute must recognize a liability for the amount that would be incurred if employees with such unused vacation time were to leave. At June 30, 2021 and 2020, this accrued vacation obligation was approximately \$379,000 and \$290,000, respectively, which is included in accounts payable and accrued expenses in the statements of financial position.

CANCER RESEARCH INSTITUTE, INC.

Notes to Financial Statements June 30, 2021 and 2020

NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[11] Paycheck Protection Program loan payable:

On March 27, 2020, Congress enacted the Coronavirus Aid Relief, and Economic Security Act ("CARES Act"). The Paycheck Protection Program ("PPP") established by the CARES Act, implemented by the U.S. Small Business Administration ("SBA"), provides businesses, including certain not-for-profit organizations, with funds to pay payroll and qualifying expenditures during the coronavirus ("COVID-19") pandemic.

There are two acceptable methods for accounting for the PPP funds received under the CARES Act. Entities can elect to treat the funds as a loan or as a conditional contribution. The Institute has elected to record the PPP funds as a loan under the Financial Accounting Standards Board's ("FASB") Accounting Standards Codification ("ASC") 470, *Debt*. The Institute is in the process of applying for loan forgiveness, which will be recognized when the application is formally approved by the bank and the SBA; however, no assurance can be provided that the Institute will be eligible for forgiveness, in whole, or in part (see Note E).

[12] Functional allocation of expenses:

The costs of providing the Institute's various programs and supporting services have been summarized on a functional basis in the statements of activities. The statements of functional expenses present expenses by function and natural classification. Accordingly, direct costs have been functionalized within the program and supporting services based on the nature of the expense. Indirect costs such as salaries, including payroll taxes and employee benefits, have been allocated based on the basis of time and effort by employees, and other indirect costs such as occupancy and depreciation have been allocated based on square footage.

[13] Income tax uncertainties:

The Institute follows the provisions of the FASB ASC *Topic 740, Income Taxes*, relating to accounting and reporting for uncertainty in income taxes. For the Institute, these provisions could be applicable to the incurrence of unrelated business income. Because of the Institute's general tax-exempt status, management believes ASC Topic 740 has not had, and is not anticipated to have, a material impact on the Institute's financial statements.

[14] Net assets:

The net assets of the Institute and changes therein are reported as follows:

(i) *Net assets without donor restrictions:*

The Institute's net assets without donor restrictions represent those resources that are not subject to donor restrictions as to their use and are available for current operations. Funds designated by the Board of Trustees are to function as an endowment and remain without restrictions, subject to the discretion of the Board of Trustees.

CANCER RESEARCH INSTITUTE, INC.

Notes to Financial Statements June 30, 2021 and 2020

NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[14] Net assets: (continued)

(ii) *Net assets with donor restrictions:*

Net assets with donor restrictions represent those resources that are subject to donor-imposed restrictions, such as specific purposes and/or the passage of time. Also included in net assets with donor restrictions are donor restrictions that are perpetual in nature and are subject to the requirements of the New York Prudent Management of Institutional Funds Act ("NYPMIFA"). These donors have stipulated that those resources be maintained in perpetuity with the resultant income and net capital appreciation arising from the underlying assets to be used in the satisfaction of the wishes of those donors. When a donor's restriction expires, that is, when a stipulated time restriction ends or a purpose restriction is accomplished or a Board appropriation has been made, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statements of activities as "net assets released from restrictions." Contributions with donor restrictions received in a fiscal period during which the underlying restrictions are also met within the same fiscal period are recorded as net assets without donor restrictions in the statements of activities.

[15] Contributions:

Contributions to the Institute are recognized as revenue upon the receipt of either cash, other assets, or of unconditional pledges. Contributions are recorded as with donor restrictions if they are received with donor stipulations or time considerations as to their use. Conditional contributions are recognized when the donor's conditions have been met by requisite actions of the Institute's management or the necessary events have taken place, and if received in advance, are recognized in the statements of financial position as funds received in advance.

The Institute records bequest income at the time it has an established right to a bequest and the proceeds are measurable. Contributions to be received over periods longer than a single year are discounted at an interest rate commensurate with the risk involved.

Gross proceeds paid by attendees at special events held as fundraising activities represent contribution revenue, as well as the payment of the direct cost of the benefit received by the attendee at the event. Special event income is reported net of the direct benefit to donors. Special event revenues, other than contributions, applicable to a current year are recognized as revenue in the year the special event takes place. Special event revenue for a future year's period is deferred and recognized when the event takes place.

The Institute has entered into various clinical research support agreements to conduct clinical trials of cancer immunotherapies. Contributions for clinical studies are recognized and recorded when the Institute recognizes the related expenses associated with the medical partners.

The Institute periodically assesses the collectability of its pledges receivable and other receivables using management's judgement regarding potential defaults; accordingly, management considers factors such as: (i) prior collection history; (ii) the type of contributions; and (iii) the nature of the clinical studies/trials, and provided allowances for anticipated losses, if any, when necessary.

CANCER RESEARCH INSTITUTE, INC.

Notes to Financial Statements June 30, 2021 and 2020

NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[16] Contributed services:

For recognition of contributed services in the financial statements, such services must: (i) create or enhance non-financial assets, (ii) typically need to be acquired if not provided by donation, (iii) require specialized skills, and (iv) be provided by individuals possessing these skills. Contributed services are recorded at their estimated fair value at the dates of donation and are reported as without donor restrictions in the statements of activities. The fair values of contributed services provided by the Institute's Scientific Advisory Council totaled \$589,448 and \$564,130 for fiscal years 2021 and 2020, respectively, and these amounts have been recorded as revenue and expense in the statements of activities. Other contributed services provided to the Institute such as those provided by volunteers, are not reported in the financial statements because they do not meet the criteria for recognition.

[17] Fellowships, investigatorships, and grants:

The Institute awards fellowships, investigatorships, and grants covering periods of one to four years for the purpose of medical research. These awards are recorded as expenses at the time they become unconditional.

[18] Science, medical and research information, and communications:

Science, medical and research information, and communications include costs primarily related to: (i) providing the public with information concerning cancer immunology, (ii) responding to inquiries from the public concerning cancer, and (iii) communicating with applicants and awardees. These awards are recorded as expenses at the time they become unconditional.

[19] Advertising costs:

The Institute expenses the costs of advertising as incurred. Advertising expenses were \$416,569 and \$258,489 during fiscal years 2021 and 2020, respectively.

[20] Adoption of accounting pronouncements:

In May 2014, the FASB issued Accounting Standards Update ("ASU") No. 2014-09, *Revenue from Contracts with Customers (Topic 606)*, which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. ASU No. 2014-09 requires an entity to recognize revenue depicting the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The standard permits the use of either the retrospective or cumulative effect transition method. Analysis of various provisions of this standard resulting in no significant changes in the way the Institute recognized revenue, and therefore no changes to the previously issued financial statements was required on a retrospective basis.

CANCER RESEARCH INSTITUTE, INC.

Notes to Financial Statements June 30, 2021 and 2020

NOTE A - THE INSTITUTE AND ITS SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

[21] Upcoming accounting pronouncements:

(i) *Contributed nonfinancial assets:*

In September 2020, the FASB issued ASU No. 2020-07, *Not-for-Profit Entities (Topic 958): Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets*, intended to improve transparency in the reporting of contributed nonfinancial assets, also known as gifts-in-kind, for not-for-profit organizations. The ASU requires a not-for-profit organization to present contributed nonfinancial assets as a separate line item in the statement of activities, apart from contributions of cash or other financial assets. For each category of contributed nonfinancial assets recognized, the not-for-profit organization will need to disclose: (i) qualitative information about whether the contributed nonfinancial assets were either monetized or utilized during the reporting period. If utilized, a description of the programs or other activities in which those assets were used; (ii) the not-for-profit's policy (if any) about monetizing rather than utilizing contributed nonfinancial assets; (iii) a description of any donor-imposed restrictions associated with the contributed nonfinancial assets; (iv) the valuation techniques and inputs used to arrive at a fair value measure, in accordance with the requirements in *Topic 820, Fair Value Measurement*, at initial recognition; and (v) the principal market (or most advantageous market) used to arrive at a fair value measure, if it is a market in which the recipient entity is prohibited by a donor-imposed restriction from selling or using the contributed nonfinancial assets. The amendments in this ASU will be applied on a retrospective basis, and are effective for annual reporting periods beginning after June 15, 2021. Management is in the process of assessing the impact of this ASU on the financial statements and related disclosures.

(ii) *Leases:*

In February 2016, the FASB issued ASU No. 2016-02, *Leases (Topic 842)*, as amended, which supersedes the current leasing guidance and upon adoption, will require lessees to recognize right-of-use assets and lease liabilities on the statement of financial position for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. Leases with a term of 12 months or less will be accounted for similar to existing guidance for operating leases today. The new standard is effective for the Institute for the annual period beginning after December 15, 2021, and can be early adopted. Upon the adoption of the guidance, operating leases are capitalized on the statement of financial position at the present value of lease payments. The statement of financial position amount recorded for existing leases at the date of adoption of ASU 2016-02 will be calculated using the applicable incremental borrowing rate at the date of adoption. The impact on the Institute's financial statements is currently being evaluated. Information about the Institute's undiscounted future lease payments and the timing of those payments is provided in Note M.

[22] Reclassification:

Certain amounts included in the prior year's financial statement have been reclassified to conform to the current year's presentation. These reclassifications had no effect on the previously reported change in net assets.

[23] Subsequent events:

The Institute evaluated subsequent events through October 15, 2021, the date on which the financial statements were available to be issued.

CANCER RESEARCH INSTITUTE, INC.

Notes to Financial Statements June 30, 2021 and 2020

NOTE B - CONTRIBUTIONS AND GRANTS AND OTHER RECEIVABLES

[1] Contributions and grants receivable:

At each fiscal year-end, contributions and grants receivable are estimated to be received as follows:

	June 30,	
	2021	2020
Gross amounts due in:		
Less than one year	\$ 16,693,441	\$ 18,225,855
One to five years	<u>21,857,448</u>	<u>20,575,609</u>
	38,550,889	38,801,464
Reduction for contributions due in excess of one year, at a 1% discount rate	<u>(353,313)</u>	<u>(377,209)</u>
	38,197,576	38,424,255
Allowance for uncollectible accounts	<u>(1,000,000)</u>	<u>(1,000,000)</u>
	<u>\$ 37,197,576</u>	<u>\$ 37,424,255</u>

Pledges receivable of \$28,330,946 and \$28,883,349 at June 30, 2021 and 2020, respectively, representing approximately 74% of the total pledge balances at each year end, were due from three donors. Included in contribution revenue for fiscal-years 2021 and 2020, was an amount of \$11,904,888 from one donor and \$5,917,456 from one donor, respectively, which represented approximately 30% and 15%, respectively, of the total operating support and revenue for each fiscal year.

[2] Bequest receivables:

Bequests receivable were \$12,090 and \$86,655 as of June 30, 2021 and 2020, respectively. All amounts are due within one year. Based on management's past experience, the receivables are expected to be fully collected, and, accordingly, no allowance for doubtful accounts has been established.

[3] Other receivables:

At each year-end, other receivables consisted of amounts due to the Institute for exchange-type transactions. All amounts are due within one year. Based on management's past experience, these receivables are expected to be fully collected, and, accordingly, no allowance for doubtful accounts has been established.

CANCER RESEARCH INSTITUTE, INC.

Notes to Financial Statements June 30, 2021 and 2020

NOTE C - INVESTMENTS AND BENEFICIAL INTEREST IN PERPETUAL TRUST

At each fiscal year-end, investments consisted of the following:

	June 30,			
	2021		2020	
	Fair Value	Cost	Fair Value	Cost
Cash equivalents	\$ 1,463,888	\$ 1,463,888	\$ 3,803,480	\$ 3,803,480
Equity securities	4,845,196	3,649,593	3,529,270	3,270,624
Mutual funds - equity securities	3,209,822	1,864,615	2,273,144	1,867,361
Mutual funds - fixed-income	3,706,683	3,483,604	2,028,550	1,876,641
Exchange traded funds - equity	5,409,777	3,914,453	5,054,056	4,815,327
Limited partnerships and limited liability companies [a]	<u>56,205,116</u>	<u>32,211,414</u>	41,460,698	28,540,809
	<u>\$ 74,840,482</u>	<u>\$ 46,587,567</u>	<u>\$ 58,149,198</u>	<u>\$ 44,174,242</u>

[a] The limited partnerships and limited liability companies consist of hedge funds, private equities, and fund-of-funds that primarily invest in domestic and international securities, derivative contracts, and other investments across various classes, sectors, and geographies.

At June 30, 2021 and 2020, concentrations of the Institute's investments in excess of 10% of the fair value of its portfolio included approximately 75% and 71%, respectively, invested in limited partnerships and limited liability companies.

During each fiscal year, the net investment return from investments and its classification in the accompanying statements of activities was as follows:

	Year Ended June 30,	
	2021	2020
Interest and dividends	\$ 255,844	\$ 603,256
Net realized and unrealized gains	17,096,248	979,792
Investment advisory fees	<u>(1,025,680)</u>	<u>(446,545)</u>
	16,326,412	1,136,503
Less: net investment allocation for current operations	<u>(2,931,434)</u>	<u>(2,901,985)</u>
Net investment income in excess of (less than) investment allocation	<u>\$ 13,394,978</u>	<u>\$ (1,765,482)</u>

CANCER RESEARCH INSTITUTE, INC.

Notes to Financial Statements June 30, 2021 and 2020

NOTE C - INVESTMENTS AND BENEFICIAL INTEREST IN PERPETUAL TRUST (CONTINUED)

The FASB's ASC *Topic 820, Fair Value Measurements*, establishes a three-level valuation hierarchy of fair-value measurements. These valuation techniques are based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. These two types of inputs create the following fair-value hierarchy:

- Level 1: Valuations are based on observable inputs that reflect quoted market prices in active markets for identical assets, at the reporting date.
- Level 2: Valuations are based on (i) quoted prices for similar assets in active markets, or (ii) quoted prices for those assets, or similar assets, in markets that are not active, or (iii) pricing inputs other than quoted prices that are directly or indirectly observable at the reporting date.
- Level 3: Valuations are based on pricing inputs that are unobservable and include situations where (i) there is little, if any, market activity for the assets, or (ii) the assets cannot be independently valued.

Certain of the Institute's investments are valued using NAV per share (or its equivalent unit) as a practical expedient of fair value. This applies to investments (i) which do not have a readily determinable fair value; and (ii) the financial statements of which were prepared by the respective investment managers, in a manner consistent with the measurement principles of either an investment company or an entity which has the attributes of an investment company. Investments that are valued using NAV per share (or its equivalent unit) are not required to be categorized within the fair-value hierarchy, and accordingly, investments valued at NAV have been appropriately excluded from the fair-value hierarchy.

The availability of relevant market data is monitored by the Institute's management to assess the appropriate classification of financial instruments within the fair-value hierarchy. Changes in economic conditions or valuation techniques may require the transfer of financial instruments from one level to another. In such instances, the transfer is reported at the beginning of the reporting period.

The following tables summarize the fair values of the Institute's investments and other assets at each fiscal year-end, in accordance with ASC Topic 820 valuation fair-value levels:

	June 30, 2021				
	Amounts Within Fair-Value Hierarchy			Measured at NAV	Total
	Level 1	Level 3	Total		
Investments:					
Cash equivalents	\$ 1,463,888	\$ -	\$ 1,463,888	\$ -	\$ 1,463,888
Equity securities	4,845,196	-	4,845,196	-	4,845,196
Mutual funds - equity securities	3,209,822	-	3,209,822	-	3,209,822
Mutual funds - fixed-income	3,706,683	-	3,706,683	-	3,706,683
ETFs - equity	5,409,777	-	5,409,777	-	5,409,777
Limited partnerships and LLCs	-	451,756	451,756	55,753,360	56,205,116
	18,635,366	451,756	19,087,122	55,753,360	74,840,482
Other assets:					
Beneficial interest in perpetual trust	-	806,477	806,477	-	806,477
Total	<u>\$18,635,366</u>	<u>\$ 1,258,233</u>	<u>\$19,893,599</u>	<u>\$55,753,360</u>	<u>\$75,646,959</u>

CANCER RESEARCH INSTITUTE, INC.

**Notes to Financial Statements
June 30, 2021 and 2020**

NOTE C - INVESTMENTS AND BENEFICIAL INTEREST IN PERPETUAL TRUST (CONTINUED)

	June 30, 2020				
	<u>Amounts Within Fair-Value Hierarchy</u>			Measured at NAV	
	<u>Level 1</u>	<u>Level 3</u>	<u>Total</u>	<u>Total</u>	
Investments:					
Cash equivalents	\$ 3,803,480	\$ -	\$ 3,803,480	\$ -	\$ 3,803,480
Equity securities	3,529,270	-	3,529,270	-	3,529,270
Mutual funds - equity securities	2,273,144	-	2,273,144	-	2,273,144
Mutual funds - fixed-income	2,028,550	-	2,028,550	-	2,028,550
ETFs - equity	5,054,056	-	5,054,056	-	5,054,056
Limited partnerships and LLCs	-	591,118	591,118	40,869,580	41,460,698
	16,688,500	591,118	17,279,618	40,869,580	58,149,198
Other assets:					
Beneficial interest in perpetual trust	-	653,814	653,814	-	653,814
Total	<u>\$16,688,500</u>	<u>\$ 1,244,932</u>	<u>\$17,933,432</u>	<u>\$40,869,580</u>	<u>\$58,803,012</u>

During fiscal-years 2021 and 2020, the Institute purchased approximately \$2,869 and \$216,191 of Level 3 investments, respectively. During fiscal-years 2021 and 2020, the Institute redeemed approximately \$249,899 and \$504,455 of Level 3 investments, respectively.

The following table lists investments in other investment companies by major category at June 30, 2021:

	<u>Fair Value</u>	<u>Unfunded Commitments</u>	<u>Redemption Frequency</u>	<u>Redemption Notice Period</u>
Private equity funds	\$ 23,286,093	\$ 12,574,009	N/A	Upon liquidation
Multiple hedge funds	3,368,423	-	Quarterly	30-60 Days
Multiple hedge funds	8,981,373	-	Monthly	30-90 Days
Fund-of-funds	13,310,982	-	Quarterly	95 Days
Fund-of-funds	<u>7,258,245</u>	<u>-</u>	Monthly	95 Days
	<u>\$ 56,205,116</u>	<u>\$ 12,574,009</u>		

CANCER RESEARCH INSTITUTE, INC.

Notes to Financial Statements June 30, 2021 and 2020

NOTE C - INVESTMENTS AND BENEFICIAL INTEREST IN PERPETUAL TRUST (CONTINUED)

Quantitative information regarding unobservable inputs developed by the Institute and assumptions used to measure the investments in limited partnerships, and the beneficial interest in perpetual trust as of June 30, 2021 are as follows:

Type	Fair Value	Valuation Techniques	Significant Unobservable Inputs	Range
Limited partnerships	\$ 451,756	Market approach through valuation of underlying securities	Fair value of investment assets	0.93%
Beneficial interest in perpetual trust	\$ 806,477	Market approach through valuation of underlying securities	Fair value of trust assets	8.00%

NOTE D - PROPERTY AND EQUIPMENT

At each fiscal year-end, property and equipment consisted of the following:

	June 30,	
	2021	2020
Office equipment	\$ 524,762	\$ 499,658
Leasehold improvements	<u>91,569</u>	<u>91,569</u>
	616,331	591,227
Less: accumulated depreciation and amortization	<u>(471,461)</u>	<u>(428,647)</u>
	<u>\$ 144,870</u>	<u>\$ 162,580</u>

NOTE E - PPP LOAN PAYABLE

On May 1, 2020, the Institute received \$710,150 in funds from the PPP, which is reported as a Paycheck Protection Program loan payable in the statement of financial position at June 30, 2021. The loan matures May 1, 2022, and bears interest at a rate of 1.00%. This loan may be forgiven subject to bank approval in accordance with SBA guidelines. In accordance with SBA guidelines, required monthly principal and interest payments will begin no earlier than the end of the covered period of October 2020. The Institute has ten months after the end of the covered period to apply for forgiveness of the loan. Any outstanding principle of the loan that is not forgiven under the PPP Loan program at the end of the ten-month deferral period will convert to a term loan with an interest rate of 1.00%, payable in equal installments of principal and interest over the next nine months, beginning in September 2021. As of June 30, 2021, the Institute was in the process of applying for forgiveness.

CANCER RESEARCH INSTITUTE, INC.

Notes to Financial Statements June 30, 2021 and 2020

NOTE E - PPP LOAN PAYABLE

Until determination of forgiveness, the scheduled future principal maturities as of June 30, 2021 are as follows:

<u>Fiscal-Year Ending June 30,</u>	<u>Amount</u>
2022	\$ 276,170
2023	<u>433,980</u>
Total	<u>\$ 710,150</u>

NOTE F - GRANTS AND FELLOWSHIPS PAYABLE

At each fiscal year-end, grants and fellowships payable consisted of the following:

	<u>June 30,</u>	
	<u>2021</u>	<u>2020</u>
Due to be paid within one years	\$ 35,442,972	\$ 33,193,852
Due to be paid between two and five years	<u>35,490,923</u>	<u>32,175,165</u>
	70,933,895	65,369,017
Less: present value discount of up to 1%	<u>(593,436)</u>	<u>(493,925)</u>
	<u>\$ 70,340,459</u>	<u>\$ 64,875,092</u>

NOTE G - NET ASSETS WITH DONOR RESTRICTIONS

At each fiscal year-end, net assets with donor restrictions consisted of the following:

	<u>June 30,</u>	
	<u>2021</u>	<u>2020</u>
Purpose restricted:		
Clinical and laboratory research	<u>\$ 21,858,823</u>	<u>\$ 20,749,144</u>
Perpetual in nature:		
Fellowships	2,878,390	2,878,390
Other	<u>806,477</u>	<u>653,814</u>
	<u>3,684,867</u>	<u>3,532,204</u>
	<u>\$ 25,543,690</u>	<u>\$ 24,281,348</u>

Included within net assets with donor restrictions for clinical and laboratory research is accumulated endowment income reserved for appropriation at June 30, 2021 and 2020 of \$1,269,699 and \$237,406, respectively.

CANCER RESEARCH INSTITUTE, INC.

**Notes to Financial Statements
June 30, 2021 and 2020**

NOTE G - NET ASSETS WITH DONOR RESTRICTIONS (CONTINUED)

Net assets released from restrictions during each year were for the following:

	Year Ended June 30,	
	2021	2020
Clinical and laboratory research	\$ 4,158,974	\$ 4,231,083
Combined federal campaign restricted for future periods	-	100,000
	<u>\$ 4,158,974</u>	<u>\$ 4,331,083</u>

NOTE H - ACCOUNTING AND REPORTING FOR ENDOWMENTS

[1] The endowment:

The Institute's endowment funds consist of individual funds established for a variety of purposes, consisting of both donor-restricted and Board-designated funds. As required by U.S. GAAP, net assets associated with endowment funds are classified and reported based on the existence or absence of donor-imposed restrictions.

[2] Interpretation of relevant law:

As discussed in Note A[14](ii), NYPMIFA is applicable to all of the Institute's institutional funds, including its donor-restricted endowment funds. The Board of Trustees will continue to adhere to NYPMIFA's requirements.

[3] Endowment net-asset composition by type of fund, as of each fiscal year-end:

	June 30, 2021			
	Without Donor Restrictions	Amounts Subject to Appropriation	Amounts Held in Perpetuity	Total
Donor-restricted endowment funds	\$ -	\$ 1,269,699	\$ 3,684,867	\$ 4,954,566
Board-designated endowment funds	<u>5,931,228</u>	-	-	<u>5,931,228</u>
Total funds	<u>\$ 5,931,228</u>	<u>\$ 1,269,699</u>	<u>\$ 3,684,867</u>	<u>\$ 10,885,794</u>

	June 30, 2020			
	Without Donor Restrictions	Amounts Subject to Appropriation	Amounts Held in Perpetuity	Total
Donor-restricted endowment funds	\$ -	\$ 237,406	\$ 3,532,204	\$ 3,769,610
Board-designated endowment funds	<u>4,539,701</u>	-	-	<u>4,539,701</u>
Total funds	<u>\$ 4,539,701</u>	<u>\$ 237,406</u>	<u>\$ 3,532,204</u>	<u>\$ 8,309,311</u>

CANCER RESEARCH INSTITUTE, INC.

**Notes to Financial Statements
June 30, 2021 and 2020**

NOTE H - ACCOUNTING AND REPORTING FOR ENDOWMENTS (CONTINUED)

[4] Changes in endowment net assets, during each fiscal year:

	Year Ended June 30, 2021			
	Without Donor Restrictions	Amounts Subject to Appropriation	Amounts Held in Perpetuity	Total
Endowment net assets, beginning of year	\$ 4,539,701	\$ 237,406	\$ 3,532,204	\$ 8,309,311
Investment return:				
Investment income	19,375	16,838	-	36,213
Net appreciation (realized and unrealized)	<u>1,347,972</u>	<u>1,015,455</u>	<u>152,663</u>	<u>2,516,090</u>
Total investment return	1,367,347	1,032,293	152,663	2,552,303
Contributions	<u>24,180</u>	-	-	<u>24,180</u>
Endowment net assets, end of year	<u>\$ 5,931,228</u>	<u>\$ 1,269,699</u>	<u>\$ 3,684,867</u>	<u>\$ 10,885,794</u>

	Year Ended June 30, 2020			
	Without Donor Restrictions	Amounts Subject to Appropriation	Amounts Held in Perpetuity	Total
Endowment net assets, beginning of year	\$ 4,428,807	\$ 237,406	\$ 3,534,729	\$ 8,200,942
Investment return:				
Investment income	24,726	8,997	-	33,723
Net appreciation (realized and unrealized)	<u>64,468</u>	<u>201,776</u>	<u>(2,525)</u>	<u>263,719</u>
Total investment return	89,194	210,773	(2,525)	297,442
Contributions	21,700	-	-	21,700
Appropriation of endowment assets for expenditure endowment funds	<u>-</u>	<u>(210,773)</u>	<u>-</u>	<u>(210,773)</u>
Endowment net assets, end of year	<u>\$ 4,539,701</u>	<u>\$ 237,406</u>	<u>\$ 3,532,204</u>	<u>\$ 8,309,311</u>

Amounts subject to appropriation represent that portion of allocated investment income, derived from endowment assets held in perpetuity that has not yet been appropriated for expenditure by the Board of Trustees.

CANCER RESEARCH INSTITUTE, INC.

Notes to Financial Statements June 30, 2021 and 2020

NOTE H - ACCOUNTING AND REPORTING FOR ENDOWMENTS (CONTINUED)

[5] Funds with deficiencies:

Due to unfavorable market fluctuations, from time to time, the fair value of assets associated with individual donor-restricted endowment funds may decline below the historic dollar-value of the donor's original restricted contribution to be held in perpetuity. Under the terms of NYPMIFA, the Institute has no responsibility to restore such decreases in value. There were no such deficiencies at June 30, 2021 and 2020.

[6] Return objectives and risk parameters:

The Institute has adopted investment and spending policies for endowment assets that attempt to provide a predictable stream of funding to programs and other functions supported by its Board-designated endowment, while seeking to maintain the purchasing power of the Board-designated endowment assets. Under this policy, as approved by the Board of Trustees, the Board-designated endowment assets are invested in a manner that is intended to produce results that obtain a better rate of return than the major investment indexes. The two donor-restricted funds (other than the perpetual trust) generate income that is fully utilized each year for their specified programmatic activities.

[7] Strategies employed for achieving objectives:

To satisfy its long-term rate-of-return objectives, the Institute relies on a total-return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The Institute targets a diversified asset allocation within prudent risk constraints.

[8] Spending policy and related objectives:

(i) *Endowment appropriation:*

The appropriation from the endowment is based on the earnings in the respective year.

(ii) *Investment pool appropriation:*

The Board of Trustees' authorized spending from the Institute's investment pool (for restricted funds and for general operations) is 5% of the average market value of the Institute's investment portfolio over the preceding three years. In establishing this policy, the Institute considered the long-term expected return on its investment. Accordingly, over the long term, the Institute expects the current spending policy to allow its portfolio to maintain the purchasing power of the Board-designated endowment assets, as well as to provide additional real growth through investment returns. The 5% authorized spending rate was used in both fiscal-years ended June 30, 2021 and 2020. During the fiscal-year ended June 30, 2020, there were no amounts appropriated.

CANCER RESEARCH INSTITUTE, INC.

Notes to Financial Statements June 30, 2021 and 2020

NOTE I - LIQUIDITY AND AVAILABILITY OF RESOURCES

The following reflects the Institute's financial assets as of the statement of financial position date, reduced by amounts not available for general use within one year because of donor-imposed restrictions or internal designations:

	Year Ended June 30,	
	2021	2020
Cash and cash equivalents	\$ 33,017,941	\$ 29,455,207
Contributions and grants receivable, net	37,197,576	37,424,255
Bequests receivable	12,090	86,655
Other receivables	109,931	233,807
Investments (net of private placements with redemption restrictions)	<u>62,266,473</u>	<u>41,401,496</u>
Total financial assets available within one year	<u>132,604,011</u>	<u>108,601,420</u>
Less:		
Amounts unavailable for general expenditures within one year, due to:		
Restrictions by donors with purpose restrictions	(21,858,823)	(20,749,144)
Restricted by donors that are perpetual in nature	<u>(2,878,390)</u>	<u>(2,878,390)</u>
Total amounts unavailable for general expenditure within one year	<u>(24,737,213)</u>	<u>(23,627,534)</u>
Amounts unavailable to management without Board approval:		
Board-designated endowment	<u>(5,931,228)</u>	<u>(4,539,701)</u>
Total financial assets available to meet cash needs for general expenditures within one year	<u>\$ 101,935,570</u>	<u>\$ 80,434,185</u>

Liquidity policy:

The Institute has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. Additionally, the Institute has a Board-designated endowment for the growth and sustainability of the Institute whereby amounts could be made available for current operations, if necessary; however, the Institute does not intend to spend these funds for purposes other than those approved by the Board of Trustees.

CANCER RESEARCH INSTITUTE, INC.

Notes to Financial Statements June 30, 2021 and 2020

NOTE J - ALLOCATION OF JOINT COSTS OF INFORMATION MATERIALS

The Institute incurred joint costs in the placement of advertisements that amounted to \$59,601 and \$55,153 in fiscal-years 2021 and 2020, respectively. The Institute allocated such costs as follows:

	<u>June 30,</u>	
	<u>2021</u>	<u>2020</u>
Marketing and development	\$ 42,994	\$ 41,308
Science, medical and research information and communications	<u>16,607</u>	<u>13,845</u>
	<u>\$ 59,601</u>	<u>\$ 55,153</u>

NOTE K - EMPLOYEE-BENEFIT PLAN

The Institute has a defined-contribution retirement plan, which provides for the Institute to make monthly contributions of at least 5% of the compensation of eligible employees. In addition, the Institute may contribute to the plan a discretionary amount equal to a percentage of compensation, which is to be determined each plan-year by the Institute. The plan also allows the participants to make voluntary contributions up to the maximum allowed by federal tax law. During fiscal-years 2021 and 2020, the Institute contributed amounts of approximately \$295,000 and \$297,000, respectively, to the plan.

NOTE L - CREDIT RISK

Financial instruments that potentially subject the Institute to concentrations of credit risk consist principally of cash and cash-equivalents deposited in financial institutions in amounts which, from time to time, may exceed federal insurance limits. However, based on the current Federal Deposit Insurance Coverage, management believes that the Institute does not face a significant risk of loss on these accounts that might result from the failures of the financial institutions.

NOTE M - COMMITMENTS AND OTHER UNCERTAINTY

[1] Lease obligation:

The Institute is obligated under a 124-month lease agreement for office space expiring in January 2028. The lease is subject to escalation for the Institute's pro-rata share of increases in real estate taxes and operating expenses. Concurrent with the authorization of the lease agreement, the Institute entered into a sublease agreement for a portion of its office space also expiring in January 2028. In September 2017, the Institute entered into lease agreements for office equipment, which expire in September 2022. Minimum future estimated lease payments and lease income are as follows:

<u>Year Ending June 30,</u>	<u>Lease Payments</u>	<u>Lease Income</u>
2022	\$ 545,756	\$ (126,165)
2023	554,071	(134,051)
2024	556,842	(136,679)
2025	556,842	(136,679)
2026	556,842	(136,679)
Thereafter	<u>881,667</u>	<u>(216,408)</u>
Total	<u>\$ 3,652,020</u>	<u>\$ (886,661)</u>

CANCER RESEARCH INSTITUTE, INC.

**Notes to Financial Statements
June 30, 2021 and 2020**

NOTE M - COMMITMENTS AND OTHER UNCERTAINTY (CONTINUED)

[2] Other uncertainty:

The extent of the impact and effects of the recent outbreak of COVID-19 on the operation and financial performance of the Institute's business will depend on future developments, including the duration and spread of the outbreak, related travel advisories and restrictions, and the consequential potential of staff shortages, all of which are highly uncertain and cannot be predicted. If demands for the Institute's services are impacted for an extended period, the Institute's results of operations may be materially adversely affected.